InvestorsHub Logo
Followers 11
Posts 549
Boards Moderated 0
Alias Born 08/18/2017

Re: ae kusterer post# 442817

Thursday, 02/10/2022 8:14:46 AM

Thursday, February 10, 2022 8:14:46 AM

Post# of 709746

ae kusterer Thursday, 02/10/22 08:01:16 AM
Re: None 0
Post # of 442834

Basilisk Wednesday, 02/09/22 11:03:52 PM
Re: None 0
Post #
442757
of 442814
PDS Biotechnology, focused on dendritic cell-based therapy, is in three Phase 2 trials of its Versamune platform using specialized lipids and HPV-related cancer antigens in conjunction with Keytruda to stimulate tge production of CD8+ T-cells. The Versamune platform does not follow NWBO's path of growing dendritic cells, but relies on those already existing in the body. Merck is exploring more than one dendritic cell approach to prolong Keytruda's use in oncology.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News